Yohei Shirakami

EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells

Masahito Shimizu, Yohei Shirakami, Hiroyasu Sakai et al. · Cancer Letters · 2008 · 130 citations

Medicine, Cancer Biology, Oncology +16

(−)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells

Masahito Shimizu, Yohei Shirakami, Hiroyasu Sakai et al. · Chemico-Biological Interactions · 2010 · 127 citations

Medicine, Oncology, Pharmacology +12

(−)-Epigallocatechin Gallate Suppresses Azoxymethane-Induced Colonic Premalignant Lesions in Male C57BL/KsJ-<i>db/db</i> Mice

Masahito Shimizu, Yohei Shirakami, Hiroyasu Sakai et al. · Cancer Prevention Research · 2008 · 107 citations · Full text

Medicine, Oncology, Pharmacology +13

(–)‐Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor–vascular endothelial growth factor receptor axis

Yohei Shirakami, Masahito Shimizu, Seiji Adachi et al. · Cancer Science · 2009 · 102 citations · Full text

Medicine, Oncology, Pharmacology +16

Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid

Xian‐Yang Qin, Harukazu Suzuki, Masao Honda et al. · Proceedings of the National Academy of Sciences · 2018 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17